The Top Line Pulse check on Lilly's GLP-1 fortunes
16 snips
Mar 27, 2026 Fraiser Kansteiner, Fierce Pharma reporter who covered Lilly’s retatrutide data, and Kevin Dunleavy, Fierce Pharma industry reporter, discuss Lilly’s recent HSBC downgrade and market fallout. They dive into retatrutide’s diabetes and weight-loss data, tolerability questions, competitive risks from Novo and generics, and what the regulatory and commercial timeline might mean for GLP-1 positioning.
AI Snips
Chapters
Transcript
Episode notes
HSBC Says Lilly May Be Priced To Perfection
- Eli Lilly's GLP-1 dominance looked unshakeable but an HSBC downgrade revealed growing skepticism.
- HSBC argues Lilly's stock is priced to perfection and flagged risks from competition, valuation, and market-size assumptions.
Lilly's Next Wave Is Pills And Triple Agonists
- Lilly is advancing multiple next-generation incretins including a GLP-1 pill and the triple agonist retatrutide (triple G).
- Lilly sees these assets as the next commercial wave after Monjaro and Zepbound.
Analyst Lowers Lilly Target And Shrinks Market Estimates
- HSBC cut Lilly's price target and projected much smaller long-term obesity market size than consensus.
- The analyst lowered the target from about $1,200 consensus to $850 and forecast a 2032 market of $80–$120B versus $150B consensus.